

Ross MacDonald, MD Chief Medical Officer/ASVP Correctional Health Services 55 Water Street, 18<sup>th</sup> Floor New York, NY 10041 rmacdonald@nychhc.org 646-614-0075

December 22, 2017

Martha W. King Executive Director NYC Board of Correction 1 Centre Street, Room 2213 New York, NY 10007

Dear Ms. King:

In accordance with the Board of Correction's New York City Correctional Health Care Minimum Standards, Section 3-13, "Variances," the Correctional Health Services (CHS) division of the NYC Health + Hospitals requests renewal, for a 6-month period, of a continuing variance from Section 3-04(b)(2)(v)(a) of the Minimum Standards, which requires that a tuberculin skin test (TST) be administered during the intake screening process for inmates who do not have a prior history of a positive reaction to the test. The variance, first granted by the Board in July 2013, and applicable to inmates throughout the NYC correctional system, authorizes CHS to use either interferon gamma release assays (IGRA) or TST for tuberculosis screening, and to exempt from repeat screening those prisoners who have a documented negative test in the six months prior to their admission.

The new tuberculosis screening program began at the RMSC in 2011 and then at facilities housing male inmates in 2012. Since implementation of the program, we have observed that the use of IGRAs at intake is feasible and adds negligible additional time to the intake process, while saving significant time subsequently by obviating the need for post-intake follow-up of TST results and associated documentation. CHS has now had many years of experience with IGRA, which has proven to be a valuable and effective tool in controlling tuberculosis in the jail system.

Accompanying this letter is our report on the IGRA initiative as required by the terms of the variance.

The consideration of the Board members and staff is greatly appreciated in this matter.

Sincerely,

Ross MacDonald, MD Correctional Health Services

cc: Patsy Yang, DrPH

## QuantiFERON (QFT) Progress Report June 1, 2017 - November 30, 2017

Description	Male NYSIDs (6/1/2017 - 11/30/2017)	% Male	Female NYSIDs (6/1/2017 - 11/30/2017)	% Female	Total NYSIDs (6/1/2017 - 11/30/2017)	% Total
Total NYSIDs with Intakes or State Transfer w/ QFT Orders	18,625	1	2,042		20,667	
Ineligibles: (% of NYSIDs)						
State Transfers	117	0.6%	22	1.1%	139	0.7%
Positive History	1,023	5.5%	99	4.8%	1,122	5.4%
Patients had negative results in previous 6 months	1,003	5.4%	91	4.5%	1,094	5.3%
Total Ineligible Patients	2,143	11.5%	212	10.4%	2,355	11.4%
Not Tested (% of NYSIDs)			District.	- A STATE OF THE S	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Lab Result = "Test Not Performed"	12	0.1%	1	0.05%	13	0.1%
Lab Result = "Refused"	92	0.5%	15	0.7%	107	0.5%
Lab Result = "Not available/Discharged"	547	2.9%	74	3.6%	621	3.0%
Total Not Tested Patients	651	3.5%	90	4.4%	741	3.6%
Total Eligible Intakes or State Transfer w/ QFT Orders that were tested	15,831	85.0%	1,740	85.2%	17,571	85.0%
Lab Result Breakdown for Eligibles (% of Eligibles)						
Normal/Negative/Non-Reactive	15,290	96.5%	1,682	96.7%	16,962	96.5%
Abnormal/Positive/Reactive	463	2.9%	35	2.0%	498	2.8%
Indeterminate	88	0.6%	23	1.3%	111	0.6%